Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
for Ovarian Cancer
2 locations incl. Boston
Sponsor: Brigham and Women's Hospital
Sex: Female·Age: 18+
Code: NCT04701645·Phase 1·Recruiting
Gynecologic oncology Clinical Trials in Boston, MA
As of June 2026, 61 paid clinical trials are recruiting for Gynecologic oncology in Boston, Massachusetts. Gynecologic oncology studies test PARP inhibitors, antibody-drug conjugates, maintenance therapies, and immune checkpoint inhibitors for ovarian, endometrial, cervical, and other gyn cancers. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Filter results
61 clinical trials for Gynecologic oncology
·Clear filters·↓ Download CSVA Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
for Locally Advanced or Metastatic Solid Tumors
11 locations incl. San Francisco
Sponsor: Genentech, Inc.
Sex: All·Age: 18+
Code: NCT05581004·Phase 1·Recruiting
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
for Endometrial Cancer
18 locations incl. Los Angeles
Sponsor: AstraZeneca
Sex: All·Age: 18 - 130
Code: NCT05489211·Phase 2·Recruiting
A Study of XMT-1660 in Participants With Solid Tumors
for Triple Negative Breast Cancer
26 locations incl. Phoenix
Sponsor: Mersana Therapeutics
Sex: All·Age: 18+
Code: NCT05377996·Phase 1·Recruiting
Video Education With Result Dependent dIsclosure
for Genetic Testing
1 location in Boston
Sponsor: Dana-Farber Cancer Institute
Sex: All·Age: 18+
Code: NCT05225428·Recruiting
Comprehensive Outcomes for After Cancer Health
for Ovarian Cancer
7 locations incl. Gainesville
Sponsor: Pack Health
Sex: All·Age: 18+·Accepts healthy volunteers
Code: NCT05349227·Recruiting
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
for Ovarian Cancer
9 locations incl. Boston
Sponsor: M.D. Anderson Cancer Center
Sex: Female·Age: 18+
Code: NCT05287451·Recruiting
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
for Ovarian Cancer
1 location in Boston
Sponsor: Dana-Farber Cancer Institute
Sex: Female·Age: 18+
Code: NCT04997096·Recruiting
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
for Colorectal Carcinoma
21 locations incl. Birmingham
Sponsor: Children's Oncology Group
Sex: All·Age: 12 Months - 30
Code: NCT04851119·Phase 1, Phase 2·Recruiting
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
for Solid Tumor, Adult
16 locations incl. Gilbert
Sponsor: A2 Biotherapeutics Inc.
Sex: All·Age: 18+
Code: NCT04981119·Recruiting
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
for Endometrial Cancer
21 locations incl. Duarte
Sponsor: Alliance Foundation Trials, LLC.
Sex: Female·Age: 18+
Code: NCT04486352·Phase 1, Phase 2·Recruiting
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
for Breast Cancer
14 locations incl. Duarte
Sponsor: AstraZeneca
Sex: All·Age: 18+
Code: NCT05123482·Phase 1, Phase 2·Recruiting
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
for Ovarian Cancer
Drug: Cemiplimab
13 locations incl. Duarte
Sponsor: Regeneron Pharmaceuticals
Sex: Female·Age: 18+
Code: NCT04590326·Phase 1, Phase 2·Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
for Advanced Solid Tumor
32 locations incl. Irvine
Sponsor: PMV Pharmaceuticals, Inc
Sex: All·Age: 12+
Code: NCT04585750·Phase 1, Phase 2·Recruiting
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
for Solid Tumor
8 locations incl. Aurora
Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Sex: Female·Age: 18+
Code: NCT04516447·Phase 1·Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
for Ovarian Carcinoma
539 locations incl. Birmingham
Sponsor: NRG Oncology
Sex: Female·Age: 35 - 50
Code: NCT04251052·Recruiting
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
for BRCA1 Gene Mutation
11 locations incl. Chicago
Sponsor: University Medical Center Nijmegen
Sex: Female·Age: 25 - 50
Code: NCT04294927·Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
for Advanced Solid Tumor
Drug: Tulmimetostat
17 locations incl. Atlanta
Sponsor: Novartis Pharmaceuticals
Sex: All·Age: 18+
Code: NCT04104776·Phase 1, Phase 2·Recruiting
Clinical Pre-screening Protocol for Ovarian Cancer
for Ovarian Cancer
3 locations incl. Boston
Sponsor: Allarity Therapeutics
Sex: Female·Age: 18+
Code: NCT03877796·Recruiting
RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer
for Endometrial Cancer
3 locations incl. Boston
Sponsor: Dana-Farber Cancer Institute
Sex: Female·Age: 18+
Code: NCT03675893·Phase 2·Recruiting
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
for Recurrent Ovarian Cancer
Drug: Cemiplimab
11 locations incl. Birmingham
Sponsor: Regeneron Pharmaceuticals
Sex: Female·Age: 18+
Code: NCT03564340·Phase 1, Phase 2·Recruiting